| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PROC Stock Overview
Procaps Group, S.A. operates as an integrated healthcare and pharmaceutical company worldwide.
Rewards
Risk Analysis
No risks detected for PROC from our risk checks.
Procaps Group Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.13 |
| 52 Week High | US$11.98 |
| 52 Week Low | US$7.99 |
| Beta | 0.060 |
| 1 Month Change | -4.70% |
| 3 Month Change | -6.55% |
| 1 Year Change | -10.75% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.22% |
Recent News & Updates
Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)
Does the January share price for Procaps Group, S.A. ( NASDAQ:PROC ) reflect what it's really worth? Today, we will...
Shareholder Returns
| PROC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.2% | -2.5% | -6.1% |
| 1Y | -10.8% | 5.3% | 4.2% |
Return vs Industry: PROC underperformed the US Pharmaceuticals industry which returned 5.3% over the past year.
Return vs Market: PROC underperformed the US Market which returned 4.2% over the past year.
Price Volatility
| PROC volatility | |
|---|---|
| PROC Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: PROC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: PROC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 4,500 | Ruben Minski | https://www.procapsgroup.com |
Procaps Group, S.A. operates as an integrated healthcare and pharmaceutical company worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.
Procaps Group Fundamentals Summary
| PROC fundamental statistics | |
|---|---|
| Market Cap | US$1.03b |
| Earnings (TTM) | -US$45.12m |
| Revenue (TTM) | US$401.35m |
2.6x
P/S Ratio-22.8x
P/E RatioIs PROC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PROC income statement (TTM) | |
|---|---|
| Revenue | US$401.35m |
| Cost of Revenue | US$173.17m |
| Gross Profit | US$228.18m |
| Expenses | US$273.31m |
| Earnings | -US$45.12m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 56.85% |
| Net Profit Margin | -11.24% |
| Debt/Equity Ratio | 602.2% |
How did PROC perform over the long term?
See historical performance and comparisonValuation
Is Procaps Group undervalued compared to its fair value and its price relative to the market?
2.3%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PROC ($9.13) is trading below our estimate of fair value ($9.35)
Significantly Below Fair Value: PROC is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: PROC is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: PROC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PROC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PROC is overvalued based on its PB Ratio (29.3x) compared to the US Pharmaceuticals industry average (2.1x).
Future Growth
How is Procaps Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
106.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PROC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: PROC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PROC's is expected to become profitable in the next 3 years.
Revenue vs Market: PROC's revenue (11.6% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: PROC's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PROC's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Procaps Group performed over the past 5 years?
-273.1%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: PROC is currently unprofitable.
Growing Profit Margin: PROC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PROC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PROC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PROC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: PROC has a negative Return on Equity (-124.29%), as it is currently unprofitable.
Financial Health
How is Procaps Group's financial position?
Financial Position Analysis
Short Term Liabilities: PROC's short term assets ($312.9M) exceed its short term liabilities ($276.7M).
Long Term Liabilities: PROC's short term assets ($312.9M) exceed its long term liabilities ($151.7M).
Debt to Equity History and Analysis
Debt Level: PROC's net debt to equity ratio (326.3%) is considered high.
Reducing Debt: Insufficient data to determine if PROC's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable PROC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: PROC is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 74.1% per year.
Dividend
What is Procaps Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PROC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PROC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PROC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PROC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PROC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.2yrs
Average management tenure
CEO
Ruben Minski (69 yo)
46yrs
Tenure
Mr. Ruben Minski is Founded Procaps Group, S.A. in 1976 ant has been its Chief Executive Officer and serves as its Chairman. He received a Chemical Engineering degree from Northeastern University in Boston...
Leadership Team
Experienced Management: PROC's management team is seasoned and experienced (5.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Top Shareholders
Company Information
Procaps Group, S.A.'s employee growth, exchange listings and data sources
Key Information
- Name: Procaps Group, S.A.
- Ticker: PROC
- Exchange: NasdaqGM
- Founded: 1977
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.030b
- Shares outstanding: 112.82m
- Website: https://www.procapsgroup.com
Number of Employees
Location
- Procaps Group, S.A.
- 9 rue de Bitbourg
- Luxembourg City
- 1273
- Luxembourg
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/23 23:20 |
| End of Day Share Price | 2022/01/21 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.